(Q38804845)

6 September 2017

title

Prolyl isomerase Pin1 promotes survival in EGFR-mutant lung adenocarcinoma cells with an epithelial-mesenchymal transition phenotype (English)

1 reference

6 September 2017

1 reference

1 reference

8

Takashi Kojima

1 reference

6 September 2017

10

Hiroki Takahashi

1 reference

6 September 2017

Yuji Sakuma

1

1 reference

6 September 2017

Hirotaka Nishikiori

2

1 reference

6 September 2017

Sachie Hirai

3

1 reference

6 September 2017

Miki Yamaguchi

4

1 reference

6 September 2017

Gen Yamada

5

1 reference

6 September 2017

Atsushi Watanabe

6

1 reference

6 September 2017

Tadashi Hasegawa

7

1 reference

6 September 2017

Toshiro Niki

9

1 reference

6 September 2017

language of work or name

1 reference

11 January 2016

1 reference

6 September 2017

published in

Laboratory Investigation

1 reference

6 September 2017

volume

96

1 reference

6 September 2017

issue

4

1 reference

6 September 2017

page(s)

391-398

1 reference

Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer

6 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2015.155

Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2015.155

AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2015.155

AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2015.155

Rociletinib in EGFR-mutated non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2015.155

Enhanced autophagy is required for survival in EGFR-independent EGFR-mutant lung adenocarcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2015.155

A distinct role for Pin1 in the induction and maintenance of pluripotency

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2015.155

Prolyl isomerase Pin1 acts downstream of miR200c to promote cancer stem-like cell traits in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2015.155

Active Pin1 is a key target of all-trans retinoic acid in acute promyelocytic leukemia and breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2015.155

Novel mutant-selective EGFR kinase inhibitors against EGFR T790M

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2015.155

Rapid and simple detection of hot spot point mutations of epidermal growth factor receptor, BRAF, and NRAS in cancers using the loop-hybrid mobility shift assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2015.155

WZ4002, a third-generation EGFR inhibitor, can overcome anoikis resistance in EGFR-mutant lung adenocarcinomas more efficiently than Src inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2015.155

EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2015.155

The epigenetics of epithelial-mesenchymal plasticity in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2015.155

The role of Atg proteins in autophagosome formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2015.155

The dynamic nature of autophagy in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2015.155

Deconvoluting the context-dependent role for autophagy in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2015.155

PIN1 inhibits apoptosis in hepatocellular carcinoma through modulation of the antiapoptotic function of survivin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2015.155

Down-regulation of myeloid cell leukemia-1 through inhibiting Erk/Pin 1 pathway by sorafenib facilitates chemosensitization in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2015.155

The BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer Therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2015.155

International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2015.155

NKX2-1/TTF-1: an enigmatic oncogene that functions as a double-edged sword for cancer cell survival and progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2015.155

Peptidyl-prolyl cis/trans isomerase Pin1 is critical for the regulation of PKB/Akt stability and activation phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2015.155

Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2015.155

The prolyl isomerase Pin1 induces LC-3 expression and mediates tamoxifen resistance in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2015.155

Combination erlotinib-cisplatin and Atg3-mediated autophagy in erlotinib resistant lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2015.155

Role of prolyl isomerase pin1 in pathogenesis of diseases and remedy for the diseases from natural products.

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26752745

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

An activation of LC3A-mediated autophagy contributes to de novo and acquired resistance to EGFR tyrosine kinase inhibitors in lung adenocarcinoma

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26752745

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/LABINVEST.2015.155

1 reference

Dimensions Publication ID

6 September 2017

1001595300

0 references

1 reference